Venture Capital

This Gen Z startup's viral AI videos are moving education beyond simple answers, attracting millions of users and major enterprise interest.

Medtech firm TELA Bio overhauls its board with M&A and turnaround experts, signaling a major strategic shift to accelerate growth and escape losses.

MPS smashes Q1 revenue records, fueled by a 98% surge in its AI data segment. The company now eyes a massive $6 billion capacity expansion.

Contineum Therapeutics reports encouraging early data for its non-opioid drug PIPE-791, offering a potential new weapon in the fight against chronic pain.

With a new CEO who helped build Liquid Death, A-GAME Beverages is betting his CPG playbook can turn the athlete-backed brand into a national powerhouse.

A new partnership aims to make powerful FPGA chips accessible to hobbyists and startups, potentially sparking a new wave of hardware innovation.

As Kodak prepares its Q1 2026 report, investors are watching to see if its pivot to advanced materials can sustain its recent market momentum.

A major expansion of a homegrown school meals program aims to nourish children and boost local economies, turning classrooms into hubs of community growth.

As the grid faces a crisis from decentralization, data centers, and decarbonization, G&W Electric is launching a new intelligence hub to find solutions.

The Jewish Theological Seminary appoints engagement expert Rabbi Mike Uram, signaling a strategic shift to modernize and expand its reach in a changing world.

Alkeus Pharmaceuticals will present crucial data on its oral drug for Stargardt disease, a leading cause of juvenile blindness with no current cure.

The logistics firm's recognition as a climate leader highlights an industry race where sustainability is now a key competitive and strategic advantage.

A Boston biotech is using AI and targeted mRNA to program cells inside the body, aiming to make complex CAR T treatments safer and universally accessible.

Vortex Energy is advancing its Robinsons River project, aiming to turn ancient salt deposits into vital storage for Canada's burgeoning hydrogen economy.

A new study shows high success for VVT Med's ScleroSafe varicose vein treatment, but a closer look reveals the need for more long-term data.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

Swiss medtech firm CorFlow is tackling a major post-heart attack complication with two pivotal trials, aiming to create a new standard of care.

TIME recognizes Fora's disruptive platform, which empowers thousands of new entrepreneurs to redefine the travel advisor role with AI-supercharged expertise.

With new funding, DISA Technologies is scaling its unique HPSA™ tech to secure US supply chains and remediate the toxic legacy of abandoned uranium mines.

Former HHS Secretary Tommy Thompson joins Vector Science & Therapeutics, leveraging his political clout to advance a novel transdermal drug delivery platform.